Financial Performance - The group's revenue increased from RMB 5.0 million for the year ended December 31, 2024, to RMB 32.7 million for the year ended December 31, 2025, representing a growth of 554.0%[3]. - The net loss increased by RMB 44.8 million or 28.8% from RMB 155.3 million for the year ended December 31, 2024, to RMB 200.1 million for the year ended December 31, 2025[4]. - The total comprehensive loss for the year ended December 31, 2025, was RMB 200.1 million, compared to RMB 155.3 million in 2024, indicating an increase in losses of approximately 28.8%[69]. - The company recorded a total loss of RMB 200.1 million for the year ended December 31, 2025, compared to RMB 155.3 million for the previous year[50]. - The basic loss per share increased to RMB (0.44) in 2025 from RMB (0.36) in 2024, with total losses attributable to equity holders reaching RMB (200,107,000) in 2025 compared to RMB (155,292,000) in 2024[124]. Research and Development - The company has five potential first-in-class/best-in-class drugs in clinical phases I-III and one new ingredient in the whitening field, KT-939[7]. - KX-826 achieved significant milestones in clinical trials, including reaching primary endpoints with statistical significance in multiple phases[7]. - The company has developed 5 clinical-stage drugs and 1 new ingredient, obtaining clinical trial approvals in China, the United States, and other regions[19]. - KX-826, a topical AR antagonist, has shown significant efficacy in treating androgenetic alopecia, with key clinical trials achieving primary endpoints and demonstrating statistical significance and clinical relevance[21]. - The company is actively exploring commercialization pathways for KX-826 and has patented it in multiple countries, with core patent protection until September 8, 2030[19]. Clinical Trials and Product Development - The company completed the critical Phase III clinical trial for KX-826 targeting male pattern baldness, demonstrating significant efficacy and safety[13]. - The AR-PROTAC compound GT20029 gel for acne treatment successfully met primary endpoints in its Phase II clinical trial in China[8]. - The Phase II clinical trial for GT20029 in acne treatment achieved its primary endpoint with statistical significance, confirming a recommended dose of 0.5% for Phase III trials[33]. - The long-term safety clinical trial for KX-826 in China has reached its primary endpoint, showing excellent safety and efficacy results, with data expected to be announced on March 20, 2025[21]. - The company is developing GT0486, a second-generation mTOR inhibitor for treating metastatic solid tumors such as breast cancer, prostate cancer, and liver cancer[165]. Financial Position and Liquidity - The group had cash and cash equivalents of RMB 32.7 million as of December 31, 2025, and unused bank financing of RMB 50 million[5]. - The cash and cash equivalents decreased by RMB 114.7 million or 77.8% from RMB 1.474 billion as of December 31, 2024, to RMB 327.4 million as of December 31, 2025[72]. - The current ratio dropped from 103.0% as of December 31, 2024, to 43.3% as of December 31, 2025, primarily due to the decrease in cash and cash equivalents[84]. - The company plans to alleviate liquidity pressure through various measures, including renewing existing bank credit lines and exploring equity financing[17]. - The group plans to monitor liquidity reserves based on expected cash flows and may consider issuing new shares or borrowing to meet operational funding needs[90]. Marketing and Sales Strategy - The company achieved sales revenue of RMB 32.7 million during the reporting period, a year-on-year increase of approximately 554.0%, primarily driven by live e-commerce sales of the KOSHINÉ brand[16]. - The company is expanding its overseas sales channels, focusing on platforms like Amazon in the U.S. to meet the diverse needs of global cosmetic consumers[16]. - The company plans to transition its cosmetics business from R&D to commercialization, planning to allocate more resources for new product launches and global marketing[132]. - Future strategies include deepening partnerships with major e-commerce platforms like Tmall and JD, and enhancing online promotion through live streaming on platforms like Douyin and Xiaohongshu[132]. - The company aims to expand its KOL and influencer collaborations to enhance market penetration and brand visibility[133]. Administrative and Operational Expenses - Administrative expenses increased by RMB 20.3 million or 32.8% from RMB 61.8 million in 2024 to RMB 82.1 million in 2025, primarily due to an increase in impairment losses on intangible assets of RMB 24.1 million[60]. - Other income decreased by RMB 19.6 million or 89.5% to RMB 2.3 million for the year ended December 31, 2025, mainly due to reduced government subsidies[53]. - Employee benefits expenses in administrative costs decreased by RMB 7.6 million from 2024, despite an increase in overall administrative expenses[60]. - The total expenses for the year ended December 31, 2025, amounted to RMB 235,265,000, up from RMB 176,256,000 in 2024[117]. - The company did not declare or pay any dividends for the years ended December 31, 2025, and 2024[122]. Strategic Partnerships and Collaborations - The company is in strategic partnerships for the joint development of KT-939-based cosmetics with Zhejiang Funuo Pharmaceutical Co., Ltd. and Shanghai Shangmei Cosmetics Co., Ltd.[44]. - The company is negotiating business development and commercialization for KX-826 and GT20029 with multiple potential clients[49]. - The company has suspended the development of several pipeline drugs to focus resources on the dermatological candidate drug KX-826[105]. - The company is actively seeking additional equity financing and negotiating with potential investors for new share subscriptions[156]. - The group is also pursuing additional bank financing and negotiating refinancing of existing loans under similar terms[156]. Governance and Compliance - The board believes that having the same individual serve as both Chairman and CEO ensures consistent leadership and effective strategy planning[135]. - The audit committee has reviewed the financial statements and found no objections to the accounting policies adopted by the group[158]. - The company has adopted a standard code for securities trading by directors, confirming compliance throughout the reporting period[136]. - The board has resolved not to declare any final dividend for the year ending December 31, 2025 (2024: none)[160]. - The company is currently evaluating the impact of new accounting standards on its consolidated financial statements, with potential implications for presentation[110].
开拓药业(09939) - 2025 - 年度业绩